Hemorrhagic feline calicivirus
AssigneeThe Regents of the University of California
InventorsJanet E. Foley, Kate Hurley, Niels C. Pedersen
Life of this patent
Estimating the term…
Abstract
The present invention relates to a vaccine for immunization against a viral infection caused by a hemorrhagic feline calicivirus (hFCV), a novel, atypical and unusually virulent form of a calicivirus that results in a highly contagious and fatal hemorrhagic fever syndrome. The present invention further encompasses methods of immunizing cats against particular strains of hFCV.
Claims3
A method of immunizing a cat against a hemorrhagic feline calicivirus (hFCV) which comprises administering to said cat an immunologically effective dose of a composition comprising a physiologically acceptable carrier and an attenuated, killed or inactivated hFCV, wherein the hFCV, prior to attenuation, killing, or inactivation, has all the distinguishing characteristics of a virus deposited under ATCC Accession Number PTA-5798 or PTA-5797, wherein the distinguishing characteristics comprise inducing a hemorrhagic fever syndrome in cats, and inducing a cytopathic effect against Crandell feline kidney cells in the presence of anti-FCV-F9 antiserum at a dilution of 1:16 or less.
Dependencies are inferred from the claim text.